Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $829M | $165M | $-2M | $157M | -0.3% | 23258.2% | -99.7% |
| 2024 | $4M | $-562M | $-599M | $-604M | -323.3% | -98.5% | 192.0% |
| 2023 | $241M | $-176M | $-205M | $-331M | -75.7% | -1.0% | 16.6% |
| 2022 | $243M | $-162M | $-176M | $-189M | -44.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 829.45 |
| Operating Revenue | 829.45 |
| Operating Expense | 731.10 |
| Research And Development | 607.16 |
| Selling General And Administration | 121.92 |
| Total Expenses | 731.10 |
| Operating Income | 98.35 |
| Total Operating Income As Reported | 98.35 |
| EBITDA | 164.82 |
| Normalized EBITDA | 164.82 |
| EBIT | 140.89 |
| Interest Income | 37.29 |
| Interest Expense | 89.36 |
| Net Interest Income | -52.07 |
| Other Non Operating Income Expenses | 5.26 |
| Other Income Expense | 5.26 |
| Interest Income Non Operating | 37.29 |
| Interest Expense Non Operating | 89.36 |
| Net Non Operating Interest Income Expense | -52.07 |
| Pretax Income | 51.53 |
| Tax Provision | 21.42 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | 30.11 |
| Net Income From Continuing And Discontinued Operation | -1.63 |
| Net Income From Continuing Operation Net Minority Interest | -1.63 |
| Net Income | -1.63 |
| Net Income Common Stockholders | -1.63 |
| Net Income Including Noncontrolling Interests | 30.11 |
| Normalized Income | -1.63 |
| Diluted NI Availto Com Stockholders | -1.63 |
| Basic Average Shares | 133.76 |
| Diluted Average Shares | 133.76 |
| Reconciled Depreciation | 23.93 |
| Minority Interests | -31.74 |
| Depreciation Amortization Depletion Income Statement | 2.03 |
| Depreciation And Amortization In Income Statement | 2.03 |
| General And Administrative Expense | 121.92 |
| Other Gand A | 59.21 |
| Salaries And Wages | 62.70 |
| Total Other Finance Cost | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc.this co. | ARWR | $10.6B | -6491.00 | 22.72 | -0.3% | 65.92 |
| BridgeBio Pharma, Inc. | BBIO | $13.2B | -18.19 | -6.32 | 34.7% | -26.38 |
| Axsome Therapeutics, Inc. | AXSM | $11.9B | -65.03 | 134.91 | -207.5% | -70.25 |
| Madrigal Pharmaceuticals, Inc. | MDGL | $11.4B | -39.41 | 18.85 | -47.8% | -43.53 |
| Cytokinetics, Incorporated |
| 2021 | - | - | - | - | - | - | - |
| CYTK |
| $9.8B |
| - |
| - |
| 119.0% |
| - |
| The Ensign Group, Inc. | ENSG | $9.6B | 27.92 | 4.30 | 15.4% | 19.90 |
| ImmunityBio, Inc. | IBRX | $7.6B | -21.73 | -15.26 | 70.2% | -36.08 |
| Nuvalent, Inc. | NUVL | $7.4B | -17.46 | 5.95 | -34.1% | - |
| Praxis Precision Medicines, Inc. | PRAX | $7.4B | -24.34 | 8.41 | -34.5% | -21.54 |
| Peer Median | - | -21.73 | 5.95 | -9.3% | -31.23 | |